Aim immunotech announces release of the next ceo corner segment

Ocala, fla., april 25, 2024 (globe newswire) -- aim immunotech inc. (nyse american: aim) (“aim” or the “company”), today announced the next ceo corner segment has been published on the company's website. for the ceo corner segment, thomas equels, chief executive officer of aim immunotech, gave an overview of metastatic pancreatic cancer and the ongoing phase 1b/2 clinical trial combining aim's ampligen® (rintatolimod) with astrazeneca's anti-pd-l1 immune checkpoint inhibitor imfinzi® (durvalumab) for the treatment of late-stage pancreatic cancer (the “duripanc study”).
AIM Ratings Summary
AIM Quant Ranking